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Abstract
Background: Recently published data showed discrepancies beteween P53 cDNA and DNA
sequencing in glioblastomas. We hypothesised that similar discrepancies may be observed in other
human cancers.
Methods: To this end, we analyzed 23 colorectal cancers for P53 mutations and gene expression
using both DNA and cDNA sequencing, real-time PCR and immunohistochemistry.
Results: We found P53 gene mutations in 16 cases (15 missense and 1 nonsense). Two of the 15
cases with missense mutations showed alterations based only on cDNA, and not DNA sequencing.
Moreover, in 6 of the 15 cases with a cDNA mutation those mutations were difficult to detect in
the DNA sequencing, so the results of DNA analysis alone could be misinterpreted if the cDNA
sequencing results had not also been available. In all those 15 cases, we observed a higher ratio of
the mutated to the wild type template by cDNA analysis, but not by the DNA analysis. Interestingly,
a similar overexpression of P53 mRNA was present in samples with and without P53 mutations.
Conclusion: In terms of colorectal cancer, those discrepancies might be explained under three
conditions: 1, overexpression of mutated P53 mRNA in cancer cells as compared with normal cells;
2, a higher content of cells without P53 mutation (normal cells and cells showing K-RAS and/or APC
but not P53  mutation) in samples presenting P53  mutation; 3, heterozygous or hemizygous
mutations of P53 gene. Additionally, for heterozygous mutations unknown mechanism(s) causing
selective overproduction of mutated allele should also be considered. Our data offer new clues for
studying discrepancy in P53 cDNA and DNA sequencing analysis.
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Background
In a recently published study, we showed the prevalence
of the mutated P53 template by cDNA sequencing and
determination of the wild type template by DNA analysis
in glioblastomas (GBM). That investigation allowed us to
propose three plausible hypotheses to explain those dis-
crepancies: 1, the silencing of wild type mRNA transcrip-
tion; 2, the degradation of wild type mRNA; 3, the
selective overproduction of mutated mRNA [1]. We
decided to test if similar discrepancies occur in other
human cancers. For this study, colorectal cancer (CC) was
selected as a common cancer presenting frequent P53
mutations.
The  P53  gene status was evaluated by means of both
cDNA and DNA sequencing, real-time RT-PCR and immu-
nohistochemistry. This comprehensive approach allowed
us to go toward an explanation of divergent results
observed following cDNA and DNA P53 sequencing. Our
investigation also sheds new light on the discrepancies
between immunohistochemical and molecular analyses
of P53 in CC.
Methods
Tumor samples
Resected specimens from 23 patients with colorectal can-
cer who underwent resection in the Clinical Department
of Surgical Oncology, Chair of Oncology, Medical Univer-
sity of Lodz between January 1998 and December 2001
were studied.
Immediately after surgery specimens for molecular study
were taken from resected tumors and placed in liquid
nitrogen, and next stored in -80°C. The rest of resected
material was routinely fixed in 10% buffered formalin.
After 24 hour fixation specimens taken from tumors were
dehydrated through graded alcohols and acetones, cleared
in xylenes and embedded in paraffin blocks at 56°C. For
histopatological diagnosis sections 4 μm thick of forma-
line-fixed, paraffin embedded tissue were placed on poly-
L lysine coated slides and stained with hematoxylin and
eosin. All tumors were diagnosed at Department of Tumor
Pathology, Chair of Oncology, Medical University of Lodz
according to the WHO criteria.
All analyses were performed on archival material with the
approval of the Bioethics Medical University Committee
No. RNN/53/08/KE.
DNA and RNA isolation
All analyses were performed using snap-frozen tissues
stored at -80°C. DNA and RNA were co-extracted by
means of Macherey-Nagel DNA/RNA purification kit
from normal and tumor tissues. RNA samples were
treated with DNase. RNA and DNA concentrations were
measured spectrophotometrically. 100 ng of total RNA
was reverse-transcribed into single-stranded cDNA in a
final volume of 40 μl containing 50 mM DTT, 1.5 μg
oligo(dT), 0.5 mM dNTP, 40 units of RNase inhibitor and
200 units of M-MLV reverse transcriptase (Promega).
DNA and cDNA sequencing
Exons 5–8 of the P53  gene were amplified by PCR as
described before and sequenced using the dideoxy termi-
nation method and SequiTherm Excel DNA Sequencing
Kit (Epicentre Technologies) [1,2]. To verify the results of
sequencing the semi-quantitative densitometric analysis
was performed. The intensity of wild type and mutated
bands was estimated comparing to the neighbouring
bands in the same sequencing lane used as a reference.
Estimation of sequencing sensitivity
DNA samples consisting of either wild type or mutated
templates were obtained from control samples and speci-
mens containing only mutated bands respectively. More-
over, a DNA sample obtained from patient with Li-
Fraumeni syndrome (that we previously reported) was
used as an example of a 50% presence of the mutated tem-
plate [3]. Samples presenting only a mutated band (A)
and 50% presence of the mutated template (B) were
mixed with control samples (C) in the following propor-
tions expressed in percent, respectively: 100/0; 87,5/12,5;
75/25; 50/50; 25/75; 12,5/87,5; 0/100 for A/C and 50/50;
40/60; 33,3/66,6; 25/75; 12,5/87,5; 0/100 for B/C.
Immunohistochemistry
Sections 4 μm thick of formaline-fixed, paraffin embed-
ded tissue were placed on SuperFrost Plus slides (Menzel-
Glaser, Braunschweig, Germany). These were deparaffin-
ized in xylenes and rehydrated through graded alcohols.
Then, the sections were microwaved in 0.01 M sodium cit-
rate buffer, pH 6.0, twice for 10 minutes at 360W to
epitope retrieval. After the slides were rinsed in running
water, washed with TRIS buffered saline, pH 7.4, and
incubated for 1 hour at room temperature with the pri-
mary monoclonal antibody anti-P53 (clone DO-7, 1:100
dilution, DAKO, Glostrup, Denmark), and processed with
EnVision (DAKO, Glostrup, Denmark) system. Sections
were counterstained with haematoxylin, dehydrated with
ethanol and cleared in xylene. For all tumors P53 labelling
indices defined as the percentage of positive nuclei, were
determined by counting 1000 cells in high power fields
(×400). The slides were scored by two independent
pathologists. When regional heterogenity of labelling was
detected in the tumor, counting areas were chosen to
include those with the most pronounced staining.
Real-time quantitative RT-PCR
Real-time quantitative RT-PCR was performed on a Rotor
Gene 6000 instrument (Corbett, Life Sciences, Australia)BMC Cancer 2009, 9:278 http://www.biomedcentral.com/1471-2407/9/278
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for  P53  gene (TaqMan®  Gene Expression Assays no.
Hs00153340_m1 and Hs00153349_m1) with GAPDH
(TaqMan® Gene Expression Assays no. Hs99999905_m1)
used as a reference gene for normalization of the target
genes expression levels. A normalized relative expression
level for a given target gene in unknown sample versus
control sample was calculated using the method described
previously by Pfaffl et al. with pooled cDNA from all
tumor samples used as a control, according to the equa-
tion:
where ETARGET and EREF stand for the real-time PCR effi-
ciency of target and reference gene amplification, respec-
tively, and ΔCPTARGET  (control-sample) and ΔCPREF
(control-sample) denote the difference in crossing points
(CP) between unknown and control samples for a given
target and reference genes, respectively [4].
Statistical analysis
The differences in gene expression levels were evaluated
by Mann-Whitney U test. Statistical significance was
assumed for P-value ≤ 0.05.
Loss of heterozygosity (LOH) and microsatellite instability 
(MSI) analyses
Analyses were performed using paired tumor specimens
and control tissues to recognize hemizygous mutations of
P53 gene by using the following microsatellite markers:
D17S976, D17S675, D17S1828 and D17S729. Forward
primers were 5' end fluorescence-labelled. PCR was per-
formed in thermocycling conditions established individu-
ally for each pair of primers. The percentage of nontumor
cells contaminating analyzed specimens was estimated
based on LOH and MSI analysis as was already described
[5].
Results
Sequencing of cDNA shows mutation more frequently than 
sequencing of DNA
Sequencing of cDNA showed P53 missense mutations in
15 specimens and nonsense mutation in one case of 23
analyzed CC. DNA sequencing performed for 15 samples
with missense mutation detected P53 gene mutation only
in six samples, in another six cases, the mutated template
was difficult to detect, in the final two cases the DNA anal-
yses did not revealed a P53 gene alteration (for one sam-
ple DNA was not analyzed). In all cases with a P53
mutation, the increased ratio of mutated to wild type tem-
plate was observed after cDNA analyses, when compared
with DNA analyses (Figure 1, Table 1).
LOH analysis suggests presence of hemizygous P53 
mutations and a high contamination of nontumor cells
Eleven of the 16 CC cases containing P53 mutations also
showed a loss of heterozygosity on chromosome 17 p
(Table 2). Two samples with a clear gene mutation, con-
firmed on the basis of the cDNA sequencing, but not fol-
lowing the DNA analysis, showed also LOH on 17 p,
which attests to the presence of P53 hemizygous muta-
tions. LOH analyses confirmed presence of cells without
LOH at 17 p in analyzed specimens (Figure 1). The con-
tent of such cells (nontumor cells) is shown in Table 1.
Ratio
ETARGET
CPTARGET(control sample)
EREF
CPREF(contr = () −
()
Δ
Δ o ol sample) − ,
Molecular analyses of P53 gene Figure 1
Molecular analyses of P53 gene. (A) cDNA sequencing 
showing mutation (arrow) and DNA analysis confirming 
presence of wild type nucleotide only (case no. 3 in Table 1). 
(B) cDNA and DNA sequencing showing both bands equally 
(case no. 1 in Table 1). (C) cDNA sequencing showing prele-
vance of mutated nucleotide, and DNA presenting prele-
vance of wild type band (case no. 9 in Table 1). (D) 
estimation of sequencing sensitivity for sample presenting 
only mutated band, see Materials and Methods (case no. 3 in 
Table 1). (E) example of LOH analysis for microsatellite 
marker D17S675. The lost allele is marked with an arrow 
(case no.13, left and 10, right in Table 1). LOH analysis con-
firms a high amount of nontumor cells (cells without LOH on 
17 p) in sample no. 13. N, normal tissue (blood); T, tumor 
sample.BMC Cancer 2009, 9:278 http://www.biomedcentral.com/1471-2407/9/278
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As much as 25% of mutated template could escape 
detection during DNA sequencing
The analyses of sequencing sensitivity showed the muta-
tion following enrichment of mutated template by 25%
only in one case (case no. 3 in Table 1) whereas in the sec-
ond case (patient with Li-Fraumeni syndrome), the
mutated template was still difficult to detect. Based on this
data, we concluded that the presence of 25% of mutated
template can lead to misinterpretation of sequencing
results and may suggest that 25% of mutated template
could be difficult to detect during sequencing of DNA
(Figure 1).
Table 1: Results of molecular and immunohistochemical analyses of P53 gene.
No 17 p Mutation Exon Codon Effect cDNA DNA Cells without LOH 17 p Normalized relative expres-
sion level of P53 mRNA
1 LOH CGT>CAT 8 273 Arg→His WT = MT WT = MT 25–35% 3,201
2 LOH GTG>ATG 5 173 Val→Met only MT MT>WT 15–25% 2,934
3 LOH CGG>TGG 7 248 Arg→Trp only MT WT 50–60% 3,796
4 LOH CGC>CAC 5 175 Arg→His only MT WT = MT 25–35% 4,235
5 LOH CGT>CAT 8 273 Arg→His MT>WT WT = MT 25–35% 3,497
6 LOH GAG>AAG 8 285 Glu→Lys MT>WT WT 40–50% 4,443
7 U GGC>AGC 7 245 Gly→Ser only MT WT>MT - 3,005
8 ROH CGG>CAG 7 248 Arg→Gln only MT WT>MT - 3,928
9 ROH CGT>CAT 8 273 Arg→His MT>WT WT>MT - 1,692
10 LOH CGG>TGG 8 282 Arg→Trp only MT WT>MT 25–35% 3,307
11 ROH GGC>AGC 7 245 Gly→Ser MT = WT WT>MT - 2,213
12 NA ATG>ATA 7 237 Met→Ile only MT NA - 4,160
13 LOH GTG>ATG 6 216 Val→Met MT>WT WT = MT 25–35% 2,478
14 LOH GGC>AGC 7 245 Gly→Ser MT = WT WT>MT 35–45% 3,271
15 LOH CGC>CAC 5 175 Arg→His only MT WT = MT 25–35% 4,215
16 LOH negative 15–25% 2,607
17 LOH negative 25–35% 2,932
18 LOH negative 15–25% 2,606
19 LOH 13372 ins C 6 205 Frameshift WT = MT WT = MT 50–60% 1,803
20 ROH negative -4 , 0 1 7
21 LOH negative 15–25% 2,981
22 LOH negative 15–25% 1,867
23 LOH negative 25–35% 1,482
LOH, loss of heterozygosity; MT, mutated template; MT>WT, prevalence of mutated template; NA, not analyzed; WT, wild type template; WT = 
MT, equal amount of wild type and mutated template; WT>MT, prevalence of wild type template; ROH, retention of heterozygosity; U, 
uninformative (samples 1–18, positive immunohistochemistry; samples 19–23, negative immunohistochemistry).BMC Cancer 2009, 9:278 http://www.biomedcentral.com/1471-2407/9/278
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P53 mRNA is overexpressed in the subgroup of colorectal 
cancers if compared with normal tissues
P53 mRNA levels were compared among three groups:
first, cases with P53 missense mutations; second, cases
lacking of a P53 mutation, third, a control group repre-
sented by normal colon, brain and renal tissues. The dif-
ferences in gene expression levels were evaluated by the
Mann-Whitney U test. mRNA expression level was signif-
icantly higher (P = 0,0022) in the group with missense
P53 mutation as compared with the group of control tis-
sues. P53 mRNA expression was also significantly higher
(P = 0,026) in the group of cancers without a P53 muta-
tion as compared with the control group. P53 expression
was not significantly different between two groups of can-
cer samples (Figure 2).
Immunohistochemistry
18 CC cases showed P53 positive immunoreactivity,
while five cases demonstrated no immunoreactivity
(Table 1, Figure 3). 15 samples with a high P53 labelling
index showed missense mutations, but a single case with-
out P53 immunoreactivity contained a nonsense muta-
tion. P53 mRNA overexpression was observed in samples
with both positive and negative P53 immunoreactivity.
Discussion
We present here an analysis of colorectal cancer that sup-
ports our previous data published for glioblastoma, dem-
onstrating that a higher amount of mutated P53 template
is detected at the mRNA level than on the DNA level [1].
The approach based on cDNA analysis resulted in an
increase of the detection of P53 mutations in CC. Several
samples interpreted initially as ambiguous or with no P53
mutation on DNA sequencing, demonstrated mutations
following the cDNA analysis. The explanation for this dis-
crepancy could be the contamination of analyzed speci-
mens by cells with the wild type P53, combined with
mutated P53 mRNA overexpression, and a phenomenon
of P53 heterozygous or hemizygous mutations. Our data
supports this explanation. Histopathological examina-
tions and LOH analysis showed a high content of normal
cells in the majority of samples and the presence of
hemizygous P53 mutations. Real time RT-PCR analyses
confirmed the P53  mRNA overexpression in colorectal
cancer cells.
Moreover it should be realized that P53 mutation occurs
at last stage of CC tumorigenesis and is not observed in all
neoplastic cells. This issue was presented by Goranova et
al. and by Giaretti et al. [6,7]. Goranova et al. showed
samples presenting: neoplastic cells with P53 mutation,
and cells showing APC and/or K-Ras mutation but not P53
mutation [6]. Contamination or enrichment of tumor
samples by cells without P53 mutation (normal and/or
neoplastic) is obviously causing difficulties in P53 muta-
tion detection during colorectal cancer DNA analysis. In
addition similar discrepancies between P53 mRNA and
DNA analyses for breast cancers were already published
by Williams et al. [8].
Heterozygous or hemizygous mutations of P53 have been
observed frequently [9,10]. Disregard of the latter phe-
nomenon appears questionable in the light of data pre-
sented here. If a tumor sample contains 50% of tumor
cells with heterozygous mutation, only 25% of mutated
template can be detected. Similarly, a sample containing a
hemizygous mutation will show 33% of mutated tem-
plate. We showed here that the mutated template present
in the range of 25% to 30% could be really difficult to
detect during sequencing analysis. Analogous data of the
sequencing sensitivity have been already published by
Cheng and Haas [11].
Since contamination is certain and mRNA analysis pre-
vails DNA analysis, overexpression of mutated P53 mRNA
has to be accepted as logical. Our results showing domi-
nance of mutated template following the cDNA sequenc-
ing and an almost complete absence of mutated template
following the DNA analysis could not be explained only
by the elimination of wild type allele at the mRNA level.
In contrast, overexpression of mutated mRNA is suggested
by our analysis. However, we still cannot exclude that
upregulation of P53 mutated allele coexists with silencing
of the wild type allele in colorectal cancer. Overexpression
of P53 mRNA occurring both in cancer with and without
P53  mutation may result from P53  gene activation by
DNA damage, K-Ras activation, etc.
It must be stressed that the explanation of discrepancies
between the DNA and the cDNA analyses detected in CC
cannot be generalized for other cancers. Colorectal can-
cers most likely carry hemizygous mutations, whereas we
have already found that glioblastomas contain mostly
heterozygous mutations of P53. Explanatory conditions
for discrepancies between direct sequencing of the cDNA
and the DNA analyses could be applied without any addi-
tional factors only for those cases presenting hemizygous
mutations of P53. However, cases presenting the hetero-
zygous mutation require searching for mechanisms
responsible for selective overproduction of mutated P53
mRNA only. Nevertheless, from hypotheses presented for
glioblastomas, the one suggesting selective overproduc-
tion of mutated P53 seems to be most relevant to CC [1].
Our data has also shed new light on the P53 protein accu-
mulation in the context of P53 mutation. A correlation
between P53 mutations and the accumulation of P53 in
the nucleus has been observed a long time ago [12,13].
Furthermore, discrepancies between the immunohisto-
chemical and the DNA molecular analyses, analogous toBMC Cancer 2009, 9:278 http://www.biomedcentral.com/1471-2407/9/278
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those observed by us, have also been presented many
times. They were always attributed to the decreasing value
of immunohistochemistry [14-16]. Our data based on the
sequencing of both DNA and cDNA and, in addition,
immunohistochemistry did not suggest that the DNA
molecular analysis is always more robust to detect P53
mutation in CC. We suggest that cellular heterogeneity
could at least partially explain, the discrepancies observed
during the P53 immunohistochemical analysis and the
P53 DNA sequencing in favor of immunohistochemistry.
However one should be aware of the fact that already pub-
lished correlations and discrepancies between P53 accu-
mulation and P53  mutations, were analyzed in many
experimental conditions. SSCP (single strand conforma-
tion polimorphism) analysis, DHPLC (denaturing high
performance liquid chromatography) technique, direct
DNA sequencing, presence of missense and nonsense
mutaitons, etc. All these factors biase interpetation of
data, dedicated to compare immunohistochemical and
molecular analysis of P53/P53. We do not intend to over-
simplify the very complex issue of correlations between
immunohistochemical and molecular analysis. Neverthe-
less our new approach based on the cDNA analysis
increases  P53  mutation detectability and allows to
decrease the number of CC cases presenting abundant
P53 nuclear accumulation but lacking the P53 mutation.
Our data suggests that P53 mutations detection in color-
ectal cancer can be improved. We are aware that tech-
niques such as DHPLC allowing to collect the mutant
Table 2: Summary of detailed microsatellite analysis performed 
for chromosome 17 p.
No D17S1828
(3.700 kbp)
D17S675
(4.403 kbp)
D17S729
(7.156 kbp)
D17S976
(17.858 kbp)
1 ROH LOH LOH LOH
2L O H NI NI LOH
3 ROH ROH LOH NI
4L O H NI NI NI
5L O H NI NI LOH
6 LOH LOH LOH NI
7 NI NI NI NI
8 ROH ROH ROH ROH
9 ROH NI NI ROH
10 LOH LOH NI LOH
11 ROH NI NI ROH
12 NA NA NA NA
13 LOH LOH NI LOH
14 LOH NI LOH LOH
15 NI LOH NI LOH
16 LOH NI NI LOH
17 LOH LOH NI LOH
18 ROH ROH LOH LOH
19 LOH LOH NI LOH
20 ROH ROH NI ROH
21 LOH NI NI LOH
22 LOH NI NI LOH
23 LOH ROH NI LOH
LOH, loss of heterozygosity; NA, not analyzed; NI, non informative; 
ROH, retention of heterozygosity. Numbers in brackets indicate the 
distance from the centromere (kbp) determined according to HuRef 
Database. P53 (7.169 kbp) gene is located between D17S729 and 
D17S976.
P53 expression level in tumor samples with mutation and  tumor samples without mutation versus control tissue Figure 2
P53 expression level in tumor samples with mutation 
and tumor samples without mutation versus control 
tissue. Significance of difference according to Mann-Whitney 
U test, P < 0.05.
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peaks by means of fraction collection increases sensitivity
of the nucleic acid mutation detection. However it should
be remembered that this technique although very sensi-
tive, in terms of the percentage of mutated template
detected, does not allow to detect all kinds of mutations
[17-20]. To this end we recomend to increase sensitivity of
missense mutations detection by direct cDNA sequencing.
P53 cDNA DHPLC followed by sequencing of collected
mutated template should also be considered. Detection of
nonsense mutations has to be done by DNA analysis,
since decay of nonsense mutated mRNA, will negatively
influence sensitivity of cDNA analysis.
We would like to add that the observed overexpression of
P53 mRNA in colorectal cancer cells does not seem to be
responsible for P53 protein accumulation. Almost all CC
samples showed the P53 mRNA overexpression, including
samples with no P53 nuclear accumulation.
Conclusion
The most important findings of this study are as follows:
1, cDNA sequencing appears superior to DNA sequencing
in detecting P53 missense mutations in colorectal cancer;
2, colorectal cancer demonstrates overexpression of
mutated P53 mRNA; 3, positive P53 immunoreactivity in
CC, along with negative results for P53 DNA sequencing,
should not be so readily discarded in favor of the results
of DNA analysis [16,21]. We suggest that the P53 cDNA
sequencing should be applied for all cancers, since P53
mRNA analysis can increase mutation detectability.
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